

Melissa L Pilewskie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7424239/publications.pdf>

Version: 2024-02-01

57
papers

1,888
citations

257450

24
h-index

265206

42
g-index

58
all docs

58
docs citations

58
times ranked

2169
citing authors

#	ARTICLE	IF	CITATIONS
1	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3467-3474.	1.5	232
2	Axillary Nodal Management Following Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2017, 3, 549.	7.1	174
3	Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. <i>Journal of Clinical Oncology</i> , 2015, 33, 3945-3952.	1.6	153
4	Skin Flap Necrosis After Mastectomy With Reconstruction: A Prospective Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 257-264.	1.5	121
5	Margins in breast cancer: How much is enough?. <i>Cancer</i> , 2018, 124, 1335-1341.	4.1	88
6	Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?. <i>Annals of Surgical Oncology</i> , 2016, 23, 1123-1128.	1.5	82
7	MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2017, 225, 740-746.	0.5	77
8	Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection?. <i>Journal of the American College of Surgeons</i> , 2016, 222, 138-145.	0.5	68
9	Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?. <i>Annals of Surgical Oncology</i> , 2016, 23, 3487-3493.	1.5	66
10	Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy—A Rare Event. <i>JAMA Oncology</i> , 2021, 7, 1851.	7.1	61
11	Perioperative Breast MRI Is Not Associated with Lower Locoregional Recurrence Rates in DCIS Patients Treated With or Without Radiation. <i>Annals of Surgical Oncology</i> , 2014, 21, 1552-1560.	1.5	50
12	Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 2556-2562.	1.5	45
13	Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?. <i>Annals of Surgical Oncology</i> , 2016, 23, 4253-4261.	1.5	40
14	The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype. <i>Annals of Surgical Oncology</i> , 2017, 24, 3527-3533.	1.5	40
15	Effect of Margin Width on Local Recurrence in Triple-Negative Breast Cancer Patients Treated with Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 1209-1214.	1.5	39
16	Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age. <i>Annals of Surgical Oncology</i> , 2017, 24, 698-704.	1.5	39
17	Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. <i>Cancer</i> , 2018, 124, 46-54.	4.1	37
18	Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor. <i>Annals of Surgical Oncology</i> , 2019, 26, 2127-2135.	1.5	37

#	ARTICLE	IF	CITATIONS
19	Magnetic resonance imaging in patients with newly diagnosed breast cancer: A review of the literature. <i>Cancer</i> , 2014, 120, 2080-2089.	4.1	35
20	Insulin resistance contributes to racial disparities in breast cancer prognosis in US women. <i>Breast Cancer Research</i> , 2020, 22, 40.	5.0	33
21	How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?. <i>Annals of Surgical Oncology</i> , 2020, 27, 4702-4710.	1.5	31
22	The Tyrerâ€Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS. <i>Annals of Surgical Oncology</i> , 2020, 27, 736-740.	1.5	29
23	The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034). <i>Annals of Surgical Oncology</i> , 2021, 28, 2573-2578.	1.5	27
24	Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 3481-3486.	1.5	25
25	Neoadjuvant Endocrine Therapy in Clinical Practice. <i>JAMA Oncology</i> , 2021, 7, 1700.	7.1	23
26	Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance. <i>Annals of Surgical Oncology</i> , 2017, 24, 3048-3054.	1.5	22
27	Impact of Body Mass Index on Clinical Axillary Nodal Assessment in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2016, 23, 3324-3329.	1.5	21
28	National trends in contralateral prophylactic mastectomy in women with locally advanced breast cancer. <i>Journal of Surgical Oncology</i> , 2019, 119, 79-87.	1.7	20
29	Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in 20011-Eligible Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1617-1624.	1.5	20
30	Contrast-Enhanced Mammography for Screening Women after Breast Conserving Surgery. <i>Cancers</i> , 2020, 12, 3495.	3.7	16
31	Local Transdermal Delivery of Telapristone Acetate Through Breast Skin, Compared With Oral Treatment: A Randomized Doubleâ€Blind, Placeboâ€Controlled Phase II Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 728-738.	4.7	15
32	Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?. <i>Annals of Surgical Oncology</i> , 2016, 23, 2229-2234.	1.5	14
33	Applications for Breast Magnetic Resonance Imaging. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 431-449.	1.5	13
34	Age and molecular subtypes: Impact on surgical decisions. <i>Journal of Surgical Oncology</i> , 2014, 110, 8-14.	1.7	13
35	Differences between screen-detected and interval breast cancers among BRCA mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 141-148.	2.5	10
36	Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ?. <i>Annals of Surgical Oncology</i> , 2020, 27, 1844-1851.	1.5	10

#	ARTICLE	IF	CITATIONS
37	Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation. <i>Annals of Surgical Oncology</i> , 2022, 29, 1670-1679.	1.5	9
38	Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 4706-4713.	1.5	9
39	Optimal surgical management for high-risk populations. <i>Breast</i> , 2015, 24, S91-S95.	2.2	7
40	Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 968-974.	1.5	7
41	Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2019, 26, 4317-4325.	1.5	6
42	To Look or Not to Look? Axillary Imaging: Less May Be More. <i>Journal of Breast Imaging</i> , 2021, 3, 666-671.	1.3	5
43	Breast Cancer in the Elderly: Is MRI Helpful?. <i>Breast Journal</i> , 2015, 21, 651-657.	1.0	4
44	Reply to "Implications of abnormal preoperative axillary imaging in the post Z011 era". <i>Gland Surgery</i> , 2016, 5, 453-454.	1.1	3
45	Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 275-282.	2.5	3
46	Association of Insulin Resistance and Higher Oncotype DX Recurrence Score. <i>Annals of Surgical Oncology</i> , 2021, 28, 5941-5947.	1.5	3
47	Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial: A Reply. <i>Annals of Surgical Oncology</i> , 2017, 24, 568-569.	1.5	2
48	Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 257-264.	2.5	2
49	ASO Author Reflections: Avoiding an Axillary Lymph Node Dissection: The Benefit of Neoadjuvant Chemotherapy for Occult Primary Breast Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 865-866.	1.5	1
50	ASO Author Reflections: Conceptualizing Risk in Women with Lobular Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2020, 27, 1852-1853.	1.5	1
51	The Effect of Margin Width on Local Recurrence of Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 32-37.	1.0	0
52	ASO Author Reflections: Variation in the Use of Chemoprevention According to Breast Cancer Risk Factor. <i>Annals of Surgical Oncology</i> , 2019, 26, 616-616.	1.5	0
53	ASO Author Reflections: Breast Cancer Risk Assessment in Women with LCIS "More Work Is Needed. <i>Annals of Surgical Oncology</i> , 2020, 27, 741-742.	1.5	0
54	ASO Author Reflections: Nodal Downstaging and Conversion to Breast-Conserving Surgery Following Neoadjuvant Endocrine Therapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 693-694.	1.5	0

#	ARTICLE	IF	CITATIONS
55	ASO Author Reflections: Observation After a Core Biopsy Diagnosis of Classic-Type LCIS Is a Safe Standard of Practice. <i>Annals of Surgical Oncology</i> , 2022, 29, 1680-1681.	1.5	0
56	ASO Visual Abstract: Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation. <i>Annals of Surgical Oncology</i> , 2022, 29, 1682-1682.	1.5	0
57	Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2022, , .	2.5	0